GSK buys full rights to make COVID, influenza vaccines from CureVac

CureVac NV

03/07/2024 07:08

July 3 (Reuters) - GSK  GSK.L  has bought the full
rights to develop and manufacture mRNA-based candidate vaccines
for influenza and COVID-19 from CureVac for up to 1.05 billion
euros ($1.13 billion), it said on Wednesday.
    GSK and CureVac started collaborating in 2020 to develop
mRNA-based vaccines for infectious diseases.
 
 ($1 = 0.9313 euros)

 (Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio
D'Souza)
 ((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))